Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition
about
Realistic expectations of prepulse inhibition in translational models for schizophrenia research.Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.Tspyl2 Loss-of-Function Causes Neurodevelopmental Brain and Behavior Abnormalities in Mice.GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for SchizophreniaDifferential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations.Removal of GABA(A) receptor γ2 subunits from parvalbumin neurons causes wide-ranging behavioral alterations.Prepulse inhibition and genetic mouse models of schizophrenia.Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups.Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.The protein kinase KIS impacts gene expression during development and fear conditioning in adult mice.Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 Receptor Blockade.Combined subunit-specific and unspecific inhibition of NMDA receptors triggers distinct cortical c-fos expression patterns.Parvalbumin expression and gamma oscillation occurrence increase over time in a neurodevelopmental model of NMDA receptor dysfunction
P2860
Q24645703-D46CFA37-B7B8-47A6-B690-582D03A16C58Q26830533-B7E388EC-EF44-413F-B10A-47A7D28F06F5Q27317408-0717473B-ECA9-4F60-9C85-C9745FA6AB2AQ30362301-50CEC0B7-8780-41AE-B097-CF8EF855E7BFQ30453949-B48E83AC-1744-48D4-8A66-3AD572EB916EQ30474166-848AC9F0-8664-41A7-9A45-5593071D327AQ30478270-961D7695-249C-4E0B-9F18-A1A46F549D0AQ30486391-ABE461B0-874C-497E-9EB6-A8FFAD7946E9Q33957510-AB21182F-2B2D-4430-A711-9D2BA108B8D3Q34399592-5DBE1E76-02E9-4CCE-BD73-B56CC9887288Q42372881-BABA8D57-F0C8-41B0-A575-D582D0F21BF1Q48574467-6D859BBB-2BE2-4A87-908E-10F7C14DE8CAQ58718220-5567131E-7876-49D4-86BA-84838BAE928A
P2860
Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition
description
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im August 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/08/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/08/01)
@nl
наукова стаття, опублікована в серпні 2004
@uk
مقالة علمية (نشرت في أغسطس 2004)
@ar
name
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@ast
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@en
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@nl
type
label
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@ast
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@en
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@nl
prefLabel
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@ast
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@en
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@nl
P2093
P1433
P1476
Pharmacological and genetic ev ...... to disrupt prepulse inhibition
@en
P2093
Cedric Mombereau
Guy A. Higgins
John A. Kemp
Laurence Ozmen
Martine Maco
Rammy Gill
Shigetada Nakanishi
Will Spooren
P2888
P304
P356
10.1007/S00213-004-1785-Y
P577
2004-08-01T00:00:00Z
P6179
1026526986